Scientific Platforms

Restoring resident immune cells’ innate ability to recognize and destroy cancer cells.

Enhancing or modulating T-cell and other immune effector cell responses, supporting antigen presentation and immune priming, and reprogramming the tumor microenvironment are strategies being employed to disrupt tumor evasion mechanisms and enhance anti-tumor immunity across a range of cancers.

Pursuing innovative targeted and precision medicine approaches.

Creating highly selective molecules to inhibit oncogenic drivers while minimizing off-target effects. Advancing precision medicine approaches informed by the genetic and molecular features driving patients’ tumors. Developing therapies and combinations that address intrinsic and acquired resistance, with the aim of enabling more durable responses.

Targeting cancer-specific DDR dependencies and exploiting high levels of tumor replication stress to identify novel molecules and rational DDR inhibitor combinations that prevent reliance on compensatory repair pathways, potentiate DNA damage, enhance tumor sensitivity to DNA-damaging chemotherapies and radiotherapy, and induce cancer cell death.

Enabling selective delivery of cytotoxic payloads to tumors.

Arming tumor-targeted antibodies with potent chemotherapy to maximize the therapeutic potential of cytotoxic payloads.

Building a pipeline of innovative cell therapies that reprogram immune cells into targeted, personalized medicines, designed to empower the immune system and generate sustained anti-tumor immune responses.

Redirecting immune cells to recognize and eradicate cancer cells.

Immune engagers physically bridge tumor antigens and immune cells to mobilize a targeted anti-tumor immune response while optimizing the therapeutic index.

A novel approach to deliver targeted radiation directly to cancer cells.

Arming tumor-targeted molecules with radioisotopes to enable the systemic delivery of radiation, inducing DNA damage and tumor-cell death.

Novel approaches to target cancer’s epigenome.

Developing epigenetic therapies to reprogram cancer cells by targeting reversible molecular modifications, thereby restoring transcriptional control and downregulating oncogenic drivers, with the potential to enhance responses when combined with other therapies and overcome resistance mechanisms.